BCM
ASMB icon

BlueCrest Capital Management’s Assembly Biosciences ASMB Stock Holding History

BlueCrest Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,012
Closed -$309K – 907
2017
Q1 		$309K Buy
+1,012
New +$248K 0.01% 519

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlueCrest Capital Management's ASMB Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Assembly Biosciences (ASMB) in Q2 2017, closing a stake of 1,012 shares — an estimated $309K sold.

BlueCrest Capital Management first reported a position in ASMB in Q1 2017 and held it in 1 quarter. The position peaked at $309K in Q1 2017. 65 funds tracked by Wall St. Rank hold ASMB as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Assembly Biosciences position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,012 Assembly Biosciences shares in Q2 2017, an estimated $309K.
  • BlueCrest Capital Management first reported a position in Assembly Biosciences in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Assembly Biosciences position peaked at $309K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.